# iSpecimen Inc.: overview ISPC · Nasdaq · CIK 1558569 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ispc.md) · [Financials](/companies/ispc/financials.md) · [Filings](/companies/ispc/filings.md) · [Insiders](/companies/ispc/insiders.md) Latest reported revenue: [$151.9k](/filings/0001213900-26-090226.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-090226). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,662](/filings/0001558370-24-014743.md) | [1,476 d](/filings/0001213900-26-038607.md) | [1,058](/filings/0001213900-26-058050.md) | [713](/filings/0001213900-26-090226.md) | [107](/filings/0001213900-25-111547.md) | [51.8 d](/filings/0001213900-26-038607.md) | [156](/filings/0001213900-26-058050.md) | [152](/filings/0001213900-26-090226.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(64.1%)](/filings/0001213900-25-111547.md) | [(395.8%) d](/filings/0001213900-26-038607.md) | [(154.9%)](/filings/0001213900-26-058050.md) | [(255.4%)](/filings/0001213900-26-090226.md) | [(2655.2%)](/filings/0001213900-25-111547.md) | [(5192.9%) d](/filings/0001213900-26-038607.md) | [(1627.1%)](/filings/0001213900-26-058050.md) | [(897.1%)](/filings/0001213900-26-090226.md) | | Net margin | % | [(54.1%)](/filings/0001213900-25-111547.md) | [(409.8%) d](/filings/0001213900-26-038607.md) | [(156.8%)](/filings/0001213900-26-090226.md) | [(146.9%)](/filings/0001213900-26-090226.md) | [(2608.7%)](/filings/0001213900-25-111547.md) | [(9662.2%) d](/filings/0001213900-26-038607.md) | [(1458.4%)](/filings/0001213900-26-090226.md) | [(896.9%)](/filings/0001213900-26-090226.md) | | Diluted EPS | $ per share | [(2.10)](/filings/0001213900-25-111547.md) | not reported | [(28.55)](/filings/0001213900-26-058050.md) | [(16.78)](/filings/0001213900-26-090226.md) | [(0.48)](/filings/0001213900-25-111547.md) | not reported | [(6.66)](/filings/0001213900-26-058050.md) | [(0.98)](/filings/0001213900-26-090226.md) | | Free cash flow | $k | [(1,094) d](/filings/0001213900-25-111547.md) | [(3,581) d](/filings/0001213900-26-038607.md) | not reported | not reported | [(2,036) d](/filings/0001213900-25-111547.md) | [(917) d](/filings/0001213900-26-038607.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.1](/filings/0001558370-23-005151.md) | [10.4](/filings/0001558370-24-003129.md) | [9.9](/filings/0001558370-24-003129.md) | [9.3](/filings/0001213900-26-038607.md) | [1.9](/filings/0001213900-26-038607.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(53.2%)](/filings/0001558370-23-005151.md) | [(97.9%)](/filings/0001558370-24-003129.md) | [(112.5%)](/filings/0001213900-25-031639.md) | [(137.0%)](/filings/0001213900-26-038607.md) | [(465.4%)](/filings/0001213900-26-038607.md) | | Net margin | % | [(80.5%)](/filings/0001558370-23-005151.md) | [(98.5%)](/filings/0001558370-24-003129.md) | [(111.8%)](/filings/0001213900-25-031639.md) | [(134.5%)](/filings/0001213900-26-038607.md) | [(543.7%)](/filings/0001213900-26-038607.md) | | Diluted EPS | $ per share | [(2.09)](/filings/0001558370-23-005151.md) | [(1.16)](/filings/0001558370-24-003129.md) | [(24.55)](/filings/0001213900-25-031639.md) | [(17.58)](/filings/0001213900-26-038607.md) | [(2.28)](/filings/0001213900-26-038607.md) | | Free cash flow | $m | [(10.7)](/filings/0001558370-23-005151.md) | [(6.0)](/filings/0001558370-24-003129.md) | [(5.8)](/filings/0001213900-25-031639.md) | [(8.3)](/filings/0001213900-26-038607.md) | [(4.2)](/filings/0001213900-26-038607.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ispc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $84.9k | 32,037 | | New +32,037 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $64.7k | 24,414 | | New +24,414 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $580 | 219 | | New +219 | | [IFP Advisors, Inc](/funds/1641866.md) | 2026-06-30 | $530 | 200 | | New +200 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $188 | 71 | | New +71 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $82 | 31 | | New +31 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $5 | 2 | | New +2 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $3 | 1 | | New +1 | ## Recent filings [All 331 filings](/companies/ispc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-09 | 16:30 ET | [8-K](/filings/0001213900-26-108501.md) | 5.07 Shareholder vote results | 0001213900-26-108501 | | 2026-09-14 | 17:00 ET | [DEF 14A](/filings/0001213900-26-099770.md) | Proxy statement, period 2026-10-09 | 0001213900-26-099770 | | 2026-09-10 | 17:00 ET | [8-K](/filings/0001213900-26-098847.md) | 3.01 Delisting notice | 0001213900-26-098847 | | 2026-09-04 | 16:48 ET | [8-K](/filings/0001213900-26-097726.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-097726 | | 2026-08-31 | 17:22 ET | [8-K](/filings/0001213900-26-095801.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-095801 | | 2026-08-14 | 17:15 ET | [8-K](/filings/0001213900-26-090273.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-090273 | | 2026-08-14 | 17:00 ET | [10-Q](/filings/0001213900-26-090226.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090226 | | 2026-08-11 | 17:20 ET | [8-K](/filings/0001213900-26-087877.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-087877 | | 2026-08-07 | 17:00 ET | [8-K](/filings/0001213900-26-086768.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-086768 | | 2026-07-17 | 20:45 ET | [S-1/A](/filings/0001213900-26-078869.md) | Registration statement, amended | 0001213900-26-078869 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-038607.md), filed Apr 1, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1db5132c-61f3-4ef4-9db6-8f259e811dd7) ## About the filer - CIK: 1558569 - Tickers: ISPC - Exchange: Nasdaq - SIC code: 8731 Services-Commercial Physical & Biological Research - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:03 ET. No prices; not investment advice.